Monte Rosa Therapeutics (GLUE) Depreciation & Amortization (CF) (2020 - 2026)

Monte Rosa Therapeutics' Depreciation & Amortization (CF) history runs 7 years deep, the most recent figure standing at $2.0 million for Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) fell 0.93% year-over-year to $2.0 million in Q1 2026; TTM through Mar 2026 was $8.3 million, a 0.79% increase from a year earlier, with the FY2025 full-year figure at $8.4 million, up 2.89% from the prior year.
• Depreciation & Amortization (CF) retreated to $2.0 million in Q1 2026 per GLUE's latest filing, from $2.1 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $2.1 million in Q2 2025 and bottomed at $753000.0 in Q1 2022.
• The 5-year median for Depreciation & Amortization (CF) is $1.9 million (2024), against an average of $1.7 million.
• Across the five-year window, Depreciation & Amortization (CF) jumped 151.0% in 2022 and retreated 0.93% in 2026, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $1.0 million in 2022, then jumped by 80.1% to $1.8 million in 2023, then rose by 11.65% to $2.1 million in 2024, then advanced by 1.31% to $2.1 million in 2025, then fell by 2.83% to $2.0 million in 2026.
• Per Business Quant, the three latest GLUE Depreciation & Amortization (CF) figures stand at $2.0 million (Q1 2026), $2.1 million (Q4 2025), and $2.1 million (Q3 2025).